Clinical Trials in Boston

Showing 721-740 of 15,299 trials

Revumenib in Combination With 7+3 + Midostaurin in AML

NCT06313437

This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaurin) to participants with newly diagnosed Nucleophosmin (NPM1) and FMS-like tyrosine kinase 3 (FLT3) mutated Acute Myeloid Leukemia (AML). The names of the study drugs involved in this study are: * Revumenib (SNDX-5613) (a type of menin inhibitor) * Midostaurin (a type of multi-kinase including FLT3 inhibitor) * Cytarabine (a type of antineoplastic agent) * Daunorubicin (a type of antineoplastic agent)

Acute Myeloid LeukemiaAML, AdultAML With Gene Mutations+2 more

Richard Stone, MD22 participantsStarted Dec 2024

New Haven, Connecticut, United States • Boston, Massachusetts, United States

RECRUITINGPhase 2< 1 mile

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

NCT07123090

The goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants with advanced clear cell renal cell carcinoma (ccRCC) or translocation renal cell carcinoma (tRCC). The name of the study drugs involved in this research study is: * Sasanlimab (a type of monoclonal antibody) * Palbociclib (a type of kinase inhibitor) * Axitinib (a type of Vascular endothelial growth factor inhibitor)

Metastatic Renal Cell CarcinomaMetastatic Renal CancerRenal Cell Carcinoma+3 more

Stephanie Berg25 participantsStarted Nov 2025

Boston, Massachusetts, United States • Boston, Massachusetts, United States

Revumenib in Combination With 7+3 + Midostaurin in AML

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

Find Trials by Condition in Boston

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

Serum Potassium Prediction Using Machine Learning and Single-lead ECG

A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

Evaluation of Safety and Efficacy of Micro-coring Device for Treatment of Facial Wrinkles and Skin Laxity

A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

A Study of Doxycycline to Treat Chlamydial Infection

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors